You are here

Article Text

Article menu
Letter
Rapid improvement of chronic interstitial keratitis with acitretin
  1. M Labetoulle1,
  2. H Offret1,
  3. I Bournerias2,
  4. E Frau3
  1. 1Department of Ophthalmology, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, 94275 Le Kremlin-Bicêtre Cedex, France
  2. 2Department of Dermatology, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, 94010 Creteil Cedex, France
  3. 3Department of Ophthalmology, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, 94275 Le Kremlin-Bicêtre Cedex, France
  1. Correspondence to: Marc Labetoulle, Service d’Ophtalmologie, Hôpital de Bicêtre, 94275, Le Kremlin-Bicêtre Cedex, France; marc.labetoulle{at}gv.cnrs-gif.fr

https://doi.org/10.1136/bjo.86.12.1445-a

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Acitretin, a synthetic aromatic retinoid which regulates the proliferation, differentiation, and keratinisation of epidermal cells, is usually used to treat severe psoriasis or ichthyosis. The main side effects are teratogenesis and mucocutaneous forms of xerosis such as cheilitis and blepharoconjunctivitis.1,2 The biological effects of acitretin in non-epidermal cell lines, and especially those derived from ocular tissues,3,4 could explain the beneficial actions of acitretin in diseases other than skin disorders. We report a drastic improvement in tuberculosis related interstitial keratitis in a patient treated with acitretin for severe psoriasis.

    Case Report

    A 21 year old Moroccan man was referred to our ophthalmology department in 1992 …

    View Full Text

    Footnotes

    • Grant supports: None.

    • Proprietary interest: None.